Immediate and deferred switching from a boosted protease inhibitor to a dolutegravir regimen in HIV + patients is found to be highly efficacious.
Bilirubin appeared to be inversely associated with cardiovascular disease in individuals with HIV enrolled in the Veterans Aging Cohort Study.
The Copenhagen Co-morbidity in HIV Infection (COCOMO) study assessed the association between risk factors for cardiovascular disease and HIV infection.
A meta-analysis sought to determine the effect of influenza vaccination on cardiac-related mortality in patients with heart failure.
Community-acquired pneumonia and other acute infections can cause or exacerbate cardiovascular complications.
Findings confirm that cardiovascular complications related to commonly-administered, live viral vaccination are rare in adults.
HCV eradication by DAA improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Undergoing cardiac surgery during the influenza season is associated with increased risk of ARDS.
The recommendation was made after the FDA reviewed the results of a 10-year follow-up of the CLARICOR trial, which investigated the effects of clarithromycin in patients with stable coronary heart disease.
In a self-controlled case series, patients were observed to have increased incidence of hospital admissions for acute myocardial infarction within 7 days of respiratory virus detection.
A new study sought to qualify the adherence to evidence-based cardiovascular care guidelines for patients living with HIV.
HIV-infected people with unsuppressed HIV virus or low CD4 cell counts had a higher prevalence of increased pulmonary artery systolic pressure than uninfected people.
Findings show that HIV status was associated with an increased rate of incidental carotid plaque, noncalcified plaque, and high-risk plaque.
Abacavir-containing antiretroviral therapy does not appear to confer an increased risk for myocardial infarction or coronary artery disease.
Traditional risk factors may incur a higher risk for CVD in HIV-positive premenopausal women than HIV infection itself.
Cardiovascular disease risks persist for years after sepsis or pneumonia.
Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.
Dobutamine stress perfusion echocardiography can detect microvascular perfusion abnormalities that predict cardiovascular outcomes in candidates for liver transplantation.
Risk of acute myocardial infarction is 17 times higher after respiratory infection.
Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.
Patients who took azithromycin weren't any more likely to develop ventricular arrhythmia than those taking amoxicillin.
HIV poses higher risks of heart failure even at younger ages of infection, and 25% of all new cases in the United States occur in people between age 13 and 24.
No difference in warfarin requirements seen in HIV-infected and HIV-uninfected patients with venous thrombosis.
Statin use was more common among older patients, men, those with CHD, hypertension, diabetes, and patients taking NRTIs and protease inhibitors.
Elevated cardiac troponin levels were highly predictive of both in-hospital and long-term mortality in patients admitted for community-acquired pneumonia (CAP).
Persons living with HIV infection have a higher risk for cardiovascular disease; use of some antiretroviral agents can exacerbate this risk.
In preclinical animal studies, vaccination against PSCK9 lowered serum lipids and vaccination against ApoC3 lowered serum triglyceride levels.
Researchers looked at the role of concomitant pacemaker presence and the risk of infective endocarditis in patients undergoing aortic valve replacement.
Two-thirds of Venezuelan Zika patients showed evidence of heart failure after contracting the virus.
Study looking at the use of 2 frequently used protease inhibitors (atazanavir and darunavir) is suggesting that cumulative use of darunavir may be independently associated with a small but gradually increasing cardiovascular disease (CVD) risk.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Practical Tips to Improve HIV/AIDS Medication Adherence
- Threat of Zika Virus Still Significant in California
- Protective Role of Pre-F Antibodies Against RSV Acute Respiratory Infection
- HCV Neuropsychiatric Symptoms Likely Linked to Virus' Effects on Brain Function
- Prenatal Tdap Vaccination Not Associated With an Increased Risk of Autism
- Evaluation of Appropriateness of Ceftriaxone Use in the Emergency Department
- Risk Factors for Prosthetic Joint Infection Increase Likelihood for Surgical Revision
- CDC: Increase in Rate of STDs for Fourth Consecutive Year in the United States
- Effect of Respiratory Tract Microbiome on Susceptibility to Viral Infections
- Gram-Negative Bacteria Antibiotic Susceptibility for Pneumonia in the ICU
- Food Insecurity Associated With Substance Use in Women Infected With HIV
- Penicillin Allergies: Commonly Reported but Rarely Accurate
- Neisseria Meningitidis Serogroup W Infections Increasing in Georgia
- Cardiac Changes Linked With Specific ARVs in Perinatally Acquired HIV
- Physical Activity Associated With Cognitive Benefits in Women Living With HIV